Lipid News

Don’t game the system — be the system

Binks Wattenberg
October 01, 2016

Who here is tired of exchanging tales of woe about grants not funded? Most of us, I suspect. Here I will describe how a group came together to develop a plan to give lipid-related grants a fair shake while we work to increase overall funding.

Lipid researchers often feel that their grants get dinged because of a lack of expertise in lipid biology in study sections. We know that when you are an expert in a field, you have a greater appreciation for the contributions that a particular grant can make to advance the field. With this in mind, colleagues and I started an initiative to ensure that grants with a lipid focus get the expert review that they (and all grants, really) deserve.

It is lost in the mists of time exactly when and where the idea nucleated, who was there, and why I could never get the hang of the secret handshake. But in time, a notion congealed — like a vat of warm triglyceride cooling in the breeze — that instead of kvetching about the lack of lipid expertise on the study sections, the lipid community could have a role in helping provide that expertise to the National Institutes of Health and other granting bodies.

And so the Lipid Research Division, or LRD (pronounced “lard,” of course), was born. Here, I will focus on how we have leveraged the LRD to help with grant review. The effort showcases how the LRD serves as an important voice for the lipid community within the American Society for Biochemistry and Molecular Biology.

The first step was to establish a membership. The staff of the ASBMB has been phenomenal throughout this process, both in welcoming the LRD as part of the ASBMB and in providing the information technology expertise and access to their membership database that were essential. We queried the ASBMB membership for interest in joining the LRD and also included non-ASBMB members to lasso them into the ASBMB fold. We established an LRD membership list of several hundred members.

The next step was crucial. We engaged with staffers at the Center for Scientific Review at the NIH. Our pitch was simple: We want to help provide expertise, not push for more funding for lipid grants.

Several LRD steering committee members already had informally spoken with study-section scientific review officers to see if they were receptive to getting suggestions for lipid-centric reviewers. The response was overwhelmingly positive. SROs have so much to deal with. Imagine having to tell a study section full of caffeine junkies that coffee would no longer be available at the meetings. Horrors! Only slightly less onerous is ensuring that each study section is populated by the requisite expertise to review 80 grants on diverse topics using a variety of techniques. SROs do heroic duty by attending national meetings, going through meeting programs, looking through the literature and querying their contacts. They were glad for the help.

Encouraged, we went right to the top, speaking with Richard Nakamura, who is the director of CSR. He thought the idea was sound and guided us as to the qualifications they look for in reviewers and what information they could use that would help SROs find the expertise they need.

With the help of Ed Marklin, the IT wizard at the ASBMB, we used the awesome power of Survey Monkey to see who in the LRD fit the CRS’s criteria. Close to 50 of the LRD membership had NIH-eligible reviewing experience but currently were not serving. This was a treasure trove of potential lipid expertise. We transmitted the list to one of Nakamura’s advisers at the CSR, Christine Melchior, who since has customized the list for SROs for whom she is responsible.

We are not done. We also are thinking of granting bodies outside of the NIH, such as the National Science Foundation, Department of Defense and disease-specific foundations, that could use our list. We also know there are lipid experts out there who are eluding their NIH duties. We are tracking them down.

Which brings me to my last point, which is about participating in NIH review. The review process is only as good as the reviewers who wade through the grants. If an SRO invites you to review, even though you absolutely do not have the time, make some. Give up sleeping or eating: There is plenty of time for that after you retire. See you at study section. I will bring the coffee.

Binks Wattenberg

Binks Wattenberg is an associate professor in the department of biochemistry and molecular biology at Virginia Commonwealth University.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A proposal to use CRISPR to prevent opioid overdoses is a useless approach to healthcare
News

A proposal to use CRISPR to prevent opioid overdoses is a useless approach to healthcare

September 27, 2020

Nicholas McCarty of New York University writes that genetically engineering drug users’ brains is short-sighted, reactive and unnecessary.

Lessons from how the polio vaccine
News

Lessons from how the polio vaccine

September 26, 2020

Despite the polio vaccine’s long-term success, manufacturers, government leaders and the nonprofit that funded the vaccine’s development made several missteps.

From the journals: MCP
Journal News

From the journals: MCP

September 25, 2020

How marine iguanas mark their turf. A new way to study Parkinson’s disease. Glycosylation in influenza A. Read about recent papers on these topics in the journal Molecular & Cellular Proteomics.

Gut microbiome shaped by dietary sphingolipids
Journal News

Gut microbiome shaped by dietary sphingolipids

September 22, 2020

A new tracing method described in the Journal of Lipid Research offers clues on how a macronutrient interacts with the microbes that live inside us.

From the journals: JBC
Journal News

From the journals: JBC

September 21, 2020

Proteases that fire up the flu. A sulfate pocket to take out MRSA. Proteins that prompt cancer protrusions. Read about recent papers on these topics and more.

AeroNabs promise powerful, inhalable protection against COVID-19
News

AeroNabs promise powerful, inhalable protection against COVID-19

September 20, 2020

As the world awaits vaccines to bring the COVID-19 pandemic under control, UC San Francisco scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.